0
Please log in or register to do it.

Samsung Bioepis

Samsung Bioepis

(Seoul = Larose.VIP) Reporter Cho Hyun-young = Samsung Bioepis announced on the 21st that it has registered the first patient in the global phase 1 clinical trial of ‘SB27’, a biosimilar candidate for the cancer immunotherapy ‘Keytruda’.

The company plans to compare the effectiveness and safety of SB27 and Keytruda in 135 patients with non-small cell lung cancer in four countries, including Korea.

Keytruda is an immunotherapy drug used for melanoma and non-small cell lung cancer developed by global pharmaceutical company MSD. It is known to use the human immune system to suppress the proliferation of cancer cells. It is a product with annual global sales of approximately 26 trillion won in 2022.

Hong Il-seon, PE (Product Evaluation/Clinical Management) team leader at Samsung Bioepis, said, “Based on the global clinical operation know-how we have accumulated, we will do our best to complete the clinical trial in a timely manner and provide various treatment options to patients as soon as possible.” He said.

hyun0@yna.co.kr

Report to KakaoTalk okjebo 2024/02/21 08:43 Sent

Hive's new member, Aylit, debuts on the 25th of next month... Bang Si-hyuk participated in producing
The best way to diagnose breast cancer early and prevent death is... “You should get a checkup every year starting at age 40.”

Reactions

0
0
0
0
0
0
Already reacted for this post.

Reactions

Your email address will not be published. Required fields are marked *